Reports

Amid Ukraine-Russia crisis, our analysts and industry experts are closely monitoring the markets and working hard to identify, gather and timely deliver analysis of the impact of the situation and the impact that it has on various markets. All our reports are updated with the latest impact on the market before being sent out to our customers.

Global Central Nervous System Treatment Market: By Disease Type: Neurovascular Diseases, Neurodegenerative Diseases, Mental Health, Infectious Diseases, Others; By Drug Class; By Drug Type; Regional Analysis; Historical Market and Forecast (2017-2027); Market Dynamics; Competitive Landscape; Industry Events and Developments

Global Central Nervous System Treatment Market Outlook

The global central nervous system treatment market is expected to grow at a CAGR of 8.1% during the period 2022-2027. The market is likely to be driven by development of new treatment systems, regulations seeking to support treatment systems for central nervous system disorders, and technological innovations. North America, Europe and Asia are expected to be key markets.

 

Global Market Likely to be Driven by Increasing Incidence of Neurological Disorders

The nervous system comprises central nervous system (CNS) (consisting of the brain and the spinal cord) and the peripheral nervous system (consisting of nerves, including the autonomic nervous system, outside of the brain and spinal cord, including those in the arms, legs, and trunk of the body). Together, the brain and the spinal cord act as the main "processing centre" for the entire nervous system, and control all the functions of the body.

Several different medical conditions could affect the nervous system, including degenerative diseases (including Alzheimer’s disease and Parkinson’s disease), blood vessel disorders in the brain (including arteriovenous malformations and cerebral aneurysms), tumours (benign and malignant), disorders of the pituitary gland, demyelinating diseases (such as multiple sclerosis), headaches (including migraines), epilepsy, head injuries like concussions and brain trauma, movement disorders (such as tremors and Parkinson’s disease), neuro-ophthalmologic diseases (vision problems as a result from damage to the optic nerve or its connections to the brain), peripheral nerve diseases (neuropathy), spine disorders, mental disorders (such as schizophrenia), infections (such as meningitis), stroke, etc.

 

Regulatory Frameworks Looking to Facilitate Development of Personalized Medicine Expected to Drive Market Growth

Central nervous system disorders signify a key area of unmet medical need. Personalized medicine (PM) is a novel concept that seeks to capitalize on known variability in patients, which causes differences in disease susceptibility and response to medication. The European regulatory network seeks to facilitate the development of PM methods for central nervous system disorders, including biomarkers (BMs), companion diagnostics, pharmacogenomics, and rare diseases; new methodologies and innovative clinical trial designs; and advanced treatments and therapies (e.g. gene therapies, somatic cell therapies, and tissue-engineered medicines). Such developments are expected to drive the global central nervous system treatment market. Increased focus on patient centricity and participation of patient groups has led to enhanced regulatory backing, including devoted scientific advice resources, new guidance documents, and multistakeholder platforms to meet challenges in PM development. Such initiatives led to some success (e.g., BM qualification), and there is hope that these would facilitate future approval of personalized central nervous system medicines.

 

Availability of Treatment Systems and Medical Practitioners Expected to Contribute to Market Growth

Neuroradiology (a branch of neuroscience medicine) seeks to diagnose and treat nervous system problems. Treatments include balloon angioplasty and stenting of carotid or vertebral artery; intra-arterial therapy for stroke; radiation oncology of the brain and spine; endovascular embolization and coiling to treat cerebral aneurysms; kyphoplasty and vertebroplasty to treat vertebral fractures; needle biopsies, spine and soft tissues; etc. Treatment may also include medicines [possibly administered by a drug pump (like those used for people with severe muscle spasms)], deep brain stimulation, spinal cord stimulation, rehabilitation/physical therapy after brain injury or stroke, spinal surgery, etc. Availability of treatment systems, along with that of health care providers, is expected to boost the global central nervous system treatment market. Health care providers from multiple specialties may be required to treat central nervous system related conditions. These may include neurologist, vascular surgeon, neurosurgeon, neuropsychologist, pain physician, psychiatrist, psychologist, radiologist, neuroscientist, nurse practitioners (NPs), physician assistants (PAs), nutritionists or dietitians, primary care doctors, physical therapists, occupational therapists, speech-language therapists, etc.

 

Market Segmentation

By type, the market is segmented into:

  • Neurovascular Diseases (further broken down by type as given below)
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Others
  • Neurodegenerative Diseases (further broken down by type as given below)
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Mental Health (further broken down by type as given below)
    • Epilepsy 
    • Mood Disorders
    • Anxiety Disorders
    • Others
  • Infectious Diseases (further broken down by type as given below)
    • Meningitis 
    • Encephalitis 
    • Others
  • Others

By drug class, the market is divided into:

  • Immunomodulatory Drugs
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Antidepressants
  • Analgesics
  • Others

By drug type, the market is classified into:

  • Biologics
  • Non-Biologics

By region, the market is segmented into:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa

 

Key Industry Players in the Market

The report presents a detailed analysis of the following key players in the global central nervous system treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:

  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Angelini S.p.a.
  • Others

The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2021
Historical Period 2017-2021
Forecast Period 2022-2027
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Drug Class
  • Drug Type
  • Region
Breakup by Disease Type
  • Neurovascular Diseases (further broken down by type as given below)
    • Hemorrhagic Stroke
    • Ischemic Stroke
    • Others
  • Neurodegenerative Diseases (further broken down by type as given below)
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Others
  • Mental Health (further broken down by type as given below)
    • Epilepsy 
    • Mood Disorders
    • Anxiety Disorders
    • Others
  • Infectious Diseases (further broken down by type as given below)
    • Meningitis 
    • Encephalitis 
    • Others
  • Others
Breakup by Drug Class
  • Immunomodulatory Drugs
  • Interferons
  • Decarboxylase Inhibitors
  • Dopamine Agonists
  • Antidepressants
  • Analgesics
  • Others
Breakup by Drug Type
  • Biologics
  • Non-Biologics
Breakup by Region
  • North America
    • United States of America 
    • Canada
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • ASEAN
    • Australia
    • Others
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • United Arab Emirates
    • Nigeria
    • South Africa
    • Others
Market Dynamics
  • SWOT
  • Porter's Five Forces
  • Key Indicators for Demand
  • Key Indicators for Price
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Certifications
Companies Covered
  • Teva Pharmaceutical Industries Ltd.
  • Pfizer, Inc.
  • F. Hoffmann-La Roche Ltd
  • Otsuka Pharmaceutical Co., Ltd.
  • Angelini S.p.a.
  • Others
Report Price and Purchase Option Explore our purchase options that are best suited to your resources and industry needs.
Delivery Format Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option.

 

*We at Expert Market Research always strive to give you the latest information. The numbers in the article are only indicative and may be different from the actual report.

1    Preface  
2    Report Coverage – Key Segmentation and Scope
3    Report Description

    3.1    Market Definition and Outlook
    3.2    Properties and Applications
    3.3    Market Analysis
    3.4    Key Players
4    Key Assumptions
5    Executive Summary

    5.1    Overview
    5.2    Key Drivers
    5.3    Key Developments
    5.4    Competitive Structure
    5.5    Key Industrial Trends
6    Market Snapshot
    6.1    Global
    6.2    Regional
7    Industry Opportunities and Challenges
8    Global Central Nervous System Treatment Market Analysis

    8.1    Key Industry Highlights
    8.2    Global Central Nervous System Treatment Historical Market (2017-2021) 
    8.3    Global Central Nervous System Treatment Market Forecast (2022-2027)
    8.4    Global Central Nervous System Treatment Market by Disease Type
        8.4.1    Neurovascular Diseases
            8.4.1.1    Market Share
            8.4.1.2    Historical Trend (2017-2021)
            8.4.1.3    Forecast Trend (2022-2027)
            8.4.1.4    Breakup by Type
                8.4.1.4.1    Hemorrhagic Stroke
                8.4.1.4.2    Ischemic Stroke
                8.4.1.4.3    Others
        8.4.2    Neurodegenerative Diseases
            8.4.2.1    Market Share
            8.4.2.2    Historical Trend (2017-2021)
            8.4.2.3    Forecast Trend (2022-2027)
            8.4.2.4    Breakup by Type
                8.4.2.4.1    Alzheimer’s Disease
                8.4.2.4.2    Parkinson’s Disease
                8.4.2.4.3    Multiple Sclerosis
                8.4.2.4.4    Others
        8.4.3    Mental Health
            8.4.3.1    Market Share
            8.4.3.2    Historical Trend (2017-2021)
            8.4.3.3    Forecast Trend (2022-2027)
            8.4.3.4    Breakup by Type
                8.4.3.4.1    Epilepsy 
                8.4.3.4.2    Mood Disorders
                8.4.3.4.3    Anxiety Disorders
                8.4.3.4.4    Others
        8.4.4    Infectious Diseases
            8.4.4.1    Market Share
            8.4.4.2    Historical Trend (2017-2021)
            8.4.4.3    Forecast Trend (2022-2027)
            8.4.4.4    Breakup by Type
                8.4.4.4.1    Meningitis 
                8.4.4.4.2    Encephalitis 
                8.4.4.4.3    Others
        8.4.5    Others
    8.5    Global Central Nervous System Treatment Market by Drug Class
        8.5.1    Immunomodulatory Drugs 
            8.5.1.1    Market Share
            8.5.1.2    Historical Trend (2017-2021)
            8.5.1.3    Forecast Trend (2022-2027)
        8.5.2    Interferons 
            8.5.2.1    Market Share
            8.5.2.2    Historical Trend (2017-2021)
            8.5.2.3    Forecast Trend (2022-2027)
        8.5.3    Decarboxylase Inhibitors 
            8.5.3.1    Market Share
            8.5.3.2    Historical Trend (2017-2021)
            8.5.3.3    Forecast Trend (2022-2027)
        8.5.4    Dopamine Agonists 
            8.5.4.1    Market Share
            8.5.4.2    Historical Trend (2017-2021)
            8.5.4.3    Forecast Trend (2022-2027)
        8.5.5    Antidepressants 
            8.5.5.1    Market Share
            8.5.5.2    Historical Trend (2017-2021)
            8.5.5.3    Forecast Trend (2022-2027)
        8.5.6    Analgesics 
            8.5.6.1    Market Share
            8.5.6.2    Historical Trend (2017-2021)
            8.5.6.3    Forecast Trend (2022-2027)
        8.5.7    Others
    8.6    Global Central Nervous System Treatment Market by Drug Type
        8.6.1    Biologics
            8.6.1.1    Market Share
            8.6.1.2    Historical Trend (2017-2021)
            8.6.1.3    Forecast Trend (2022-2027)
        8.6.2    Non-Biologics
            8.6.2.1    Market Share
            8.6.2.2    Historical Trend (2017-2021)
            8.6.2.3    Forecast Trend (2022-2027)
    8.7    Global Central Nervous System Treatment Market by Region
        8.7.1    Market Share
            8.7.1.1    North America
            8.7.1.2    Europe
            8.7.1.3    Asia Pacific
            8.7.1.4    Latin America
            8.7.1.5    Middle East and Africa
9    Regional Analysis
    9.1    North America
        9.1.1    Historical Trend (2017-2021)
        9.1.2    Forecast Trend (2022-2027)
        9.1.3    Breakup by Country
            9.1.3.1    United States of America 
            9.1.3.2    Canada
    9.2    Europe
        9.2.1    Historical Trend (2017-2021)
        9.2.2    Forecast Trend (2022-2027)
        9.2.3    Breakup by Country 
            9.2.3.1    United Kingdom
            9.2.3.2    Germany
            9.2.3.3    France
            9.2.3.4    Italy
            9.2.3.5    Others
    9.3    Asia Pacific
        9.3.1    Historical Trend (2017-2021)
        9.3.2    Forecast Trend (2022-2027)
        9.3.3    Breakup by Country
            9.3.3.1    China
            9.3.3.2    Japan
            9.3.3.3    India
            9.3.3.4    ASEAN
            9.3.3.5    Australia
            9.3.3.6    Others
    9.4    Latin America
        9.4.1    Historical Trend (2017-2021)
        9.4.2    Forecast Trend (2022-2027)
        9.4.3    Breakup by Country
            9.4.3.1    Brazil
            9.4.3.2    Argentina
            9.4.3.3    Mexico
            9.4.3.4    Others
    9.5    Middle East and Africa
        9.5.1    Historical Trend (2017-2021)
        9.5.2    Forecast Trend (2022-2027)
        9.5.3    Breakup by Country
            9.5.3.1    Saudi Arabia
            9.5.3.2    United Arab Emirates
            9.5.3.3    Nigeria
            9.5.3.4    South Africa
            9.5.3.5    Others
10    Market Dynamics
    10.1    SWOT Analysis
        10.1.1    Strengths
        10.1.2    Weaknesses
        10.1.3    Opportunities
        10.1.4    Threats
    10.2    Porter’s Five Forces Analysis
        10.2.1    Supplier’s Power
        10.2.2    Buyer’s Power
        10.2.3    Threat of New Entrants
        10.2.4    Degree of Rivalry
        10.2.5    Threat of Substitutes
    10.3    Key Indicators for Demand
    10.4    Key Indicators for Price
11    Competitive Landscape
    11.1    Market Structure
    11.2    Company Profiles
        11.2.1    Teva Pharmaceutical Industries Ltd.
            11.2.1.1    Company Overview
            11.2.1.2    Product Portfolio
            11.2.1.3    Demographic Reach and Achievements
            11.2.1.4    Certifications
        11.2.2    Pfizer, Inc.
            11.2.2.1    Company Overview
            11.2.2.2    Product Portfolio
            11.2.2.3    Demographic Reach and Achievements
            11.2.2.4    Certifications
        11.2.3    F. Hoffmann-La Roche Ltd
            11.2.3.1    Company Overview
            11.2.3.2    Product Portfolio
            11.2.3.3    Demographic Reach and Achievements
            11.2.3.4    Certifications
        11.2.4    Otsuka Pharmaceutical Co., Ltd.
            11.2.4.1    Company Overview
            11.2.4.2    Product Portfolio
            11.2.4.3    Demographic Reach and Achievements
            11.2.4.4    Certifications
        11.2.5    Angelini S.p.a.
            11.2.5.1    Company Overview
            11.2.5.2    Product Portfolio
            11.2.5.3    Demographic Reach and Achievements
            11.2.5.4    Certifications
        11.2.6    Others
12    Industry Events and Developments

 

List of Key Figures and Tables

1.    Global Central Nervous System Treatment Market: Key Industry Highlights, 2017 and 2027
2.    Global Central Nervous System Treatment Historical Market: Breakup by Disease Type (USD Million), 2017-2021
3.    Global Central Nervous System Treatment Market Forecast: Breakup by Disease Type (USD Million), 2022-2027
4.    Global Central Nervous System Treatment Historical Market: Breakup by Drug Class (USD Million), 2017-2021
5.    Global Central Nervous System Treatment Market Forecast: Breakup by Drug Class (USD Million), 2022-2027
6.    Global Central Nervous System Treatment Historical Market: Breakup by Drug Type (USD Million), 2017-2021
7.    Global Central Nervous System Treatment Market Forecast: Breakup by Drug Type (USD Million), 2022-2027
8.    Global Central Nervous System Treatment Historical Market: Breakup by Region (USD Million), 2017-2021
9.    Global Central Nervous System Treatment Market Forecast: Breakup by Region (USD Million), 2022-2027
10.    North America Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
11.    North America Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
12.    Europe Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
13.    Europe Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
14.    Asia Pacific Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
15.    Asia Pacific Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
16.    Latin America Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
17.    Latin America Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
18.    Middle East and Africa Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2017-2021
19.    Middle East and Africa Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2022-2027
20.    Global Central Nervous System Treatment Market Structure

Key Questions Answered in the Report

The global central nervous system treatment market is projected to grow at a CAGR of 8.1% between 2022 and 2027.

The major drivers of the market include the increasing geriatric population, launch of new prospective products and pipeline drugs, favourable reimbursement policies, and improving healthcare infrastructure.

Increasing incidence of neurological disorders and regulations seeking to support treatment systems for central nervous system disorders are the key industry trends propelling the market's growth.

The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The different types of central nervous system treatment in the market are neurovascular diseases, neurodegenerative diseases, mental health, and infectious diseases, among others.

Based on drug class, the market is divided into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and analgesics, among others.

The various drug types in the market are biologics and non-biologics.

The major players in the industry are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., and Angelini S.p.a., among others.

Analyst Review

The global central nervous system treatment market was driven by the increasing incidence of neurological disorders in the historical period. Aided by the launch of new prospective products and pipeline drugs and favourable reimbursement policies, the market is expected to grow at a CAGR of 8.1% in the forecast period of 2022-2027.

EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different types of central nervous system treatment in the market are neurovascular diseases, neurodegenerative diseases, mental health, and infectious diseases, among others. Neurovascular diseases are further broken down into haemorrhagic stroke and ischemic stroke, among others while neurodegenerative diseases are sub-divided into Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, among others. Mental health is segmented into epilepsy, mood disorders, and anxiety disorders, among others, whereas infectious diseases are broken down into meningitis and encephalitis, among others. Based on drug class, the market is divided into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and analgesics, among others. The various drug types in the market are biologics and non-biologics. The major regional markets for central nervous system treatment market are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the industry are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., and Angelini S.p.a., among others.

EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.

Purchase Full Report

Mini Report

$1499
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$2699
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Five User License

$3699
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$4699
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER